NCT05829629 - Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 12, 2023

Primary Completion Date

September 30, 2025

Study Completion Date

November 30, 2025

Conditions

HPV InfectionHPV-Related Cervical Carcinoma

Interventions

BIOLOGICAL

FluBHPVE6E7

Intracervical administration for first dose followed by intramuscular administration for subsequent doses at recommended dose level and determined schedule

DRUG

Placebo

Intracervical administration for first dose followed by intramuscular administration for subsequent doses at determined schedule

Trial Locations (1)

82606

RECRUITING

Univerzitná nemocnica Bratislava, Bratislava